Business Context and Reporting Period
Company: Theriva Biologics, Inc. (TOVX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2026
Principal Office: Rockville, Maryland
Business Focus: Biopharmaceutical company developing VCN-01 (zabilugene almadenorepvec) for metastatic pancreatic ductal adenocarcinoma (PDAC).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a clinical trial milestone. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The primary material event reported is the dosing of the first patient in the VIRAGE2 clinical trial on August 6, 2026. This trial is a small proof-of-concept study evaluating more frequent repeated dosing of VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) for first-line metastatic PDAC patients.
Guidance, Outlook, and Management Commentary
- Trial Timeline: Enrollment for the VIRAGE2 trial is expected to be completed in the second half of 2026 (H2 2026).
- Data Readout: Initial pharmacodynamic and safety/tolerability data are anticipated by the third quarter of 2027 (Q3 2027).
- Strategic Rationale: The trial design is based on observations from the prior VIRAGE Phase 2b trial, where two doses of VCN-01 showed improved overall survival, progression-free survival, and duration of response compared to chemotherapy alone.
- Regulatory Context: Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have recognized the survival benefits observed with two doses and suggested that more frequent, repeated dosing could further improve clinical outcomes.
- Future Path: Results from VIRAGE2 will inform the dosing regimen for a potential future pivotal Phase 3 clinical trial.
Investor Verification Checklist
- Verify the specific dosing schedule and frequency being tested in the VIRAGE2 trial compared to the prior Phase 2b regimen.
- Monitor the enrollment progress to ensure completion aligns with the H2 2026 target.
- Review the safety profile of VCN-01 as more frequent dosing is administered, particularly regarding tolerability in combination with chemotherapy.
- Confirm the criteria for "improved clinical outcomes" that management and regulators are targeting with this dosing strategy.
- Check for any updates on the company's cash runway, as this filing does not disclose current liquidity or funding status.